2018
Phase II study of epacadostat with pembrolizumab in metastatic or unresectable gastroesophageal junction and gastric adenocarcinoma requiring paired biopsies.
Kardosh A, Tseng D, Sahaf B, Zomet A, Krupa J, Fisher G, Wang D, Mackall C, Kunz P. Phase II study of epacadostat with pembrolizumab in metastatic or unresectable gastroesophageal junction and gastric adenocarcinoma requiring paired biopsies. Journal Of Clinical Oncology 2018, 36: tps191-tps191. DOI: 10.1200/jco.2018.36.4_suppl.tps191.Peer-Reviewed Original ResearchProgression-free survivalGastroesophageal junctionOverall survivalResponse rateGastric adenocarcinomaECOG performance status 0Phase II clinical trialPDL-1 expressionPerformance status 0Single-agent pembrolizumabMedian overall survivalPD-1 inhibitorsPhase II studyIncidence of adenocarcinomaGastroesophageal junction adenocarcinomaComprehensive immune profilingMajor health problemCombination immunotherapyEligible patientsKEYNOTE-059PFS ratesPrior therapyPrior trastuzumabStatus 0Advanced disease
2014
A phase II study of capecitabine, carboplatin, and bevacizumab for metastatic or unresectable gastroesophageal junction and gastric adenocarcinoma.
Kunz P, Nandoskar P, Koontz M, Ji H, Ford J, Balise R, Kamaya A, Rubin D, Fisher G. A phase II study of capecitabine, carboplatin, and bevacizumab for metastatic or unresectable gastroesophageal junction and gastric adenocarcinoma. Journal Of Clinical Oncology 2014, 32: 115-115. DOI: 10.1200/jco.2014.32.3_suppl.115.Peer-Reviewed Original ResearchProgression-free survivalGastroesophageal junctionStable diseaseOverall survivalPartial responseGastric adenocarcinomaPrimary endpointProgressive diseaseDay 1Response rateMedian progression-free survivalCombination of capecitabineFirst tumor assessmentBest supportive careMedian overall survivalPhase II studyPromising response ratesAddition of bevacizumabIncidence of adenocarcinomaMajor health problemQuality of lifeSecondary endpointsBaseline characteristicsFree survivalGastric cardia
2012
Multi-Modality Therapy for Cancer of the Esophagus and GE Junction
Tejani MA, Burtness BA. Multi-Modality Therapy for Cancer of the Esophagus and GE Junction. Current Treatment Options In Oncology 2012, 13: 390-402. PMID: 22592595, DOI: 10.1007/s11864-012-0193-5.Peer-Reviewed Original ResearchConceptsGastroesophageal junctionNeoadjuvant platinum-based chemotherapyPostoperative adjuvant chemotherapyPlatinum-based chemotherapyIncidence of adenocarcinomaSubgroup of patientsHigh mortality rateAdjuvant chemotherapyOpinion statementCancersInduction chemotherapyNeoadjuvant treatmentPreoperative chemoradiationDistant recurrenceModality therapySystemic therapyDistal esophagusAdvanced tumorsPredictive biomarkersMortality rateTherapeutic outcomesChemotherapyEsophagusTherapyTherapy deliveryChemoradiation
1994
Time trend and the age‐period‐cohort effect on the incidence of histologic types of lung cancer in connecticut, 1960‐1989
Zheng T, Holford T, Boyle P, Chen Y, Ward B, Flannery J, Mayne S. Time trend and the age‐period‐cohort effect on the incidence of histologic types of lung cancer in connecticut, 1960‐1989. Cancer 1994, 74: 1556-1567. PMID: 8062189, DOI: 10.1002/1097-0142(19940901)74:5<1556::aid-cncr2820740511>3.0.co;2-0.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdenocarcinoma, Bronchiolo-AlveolarAdultAge FactorsAgedAged, 80 and overCarcinomaCarcinoma, Small CellCarcinoma, Squamous CellCohort EffectCohort StudiesConnecticutFemaleHumansIncidenceLung NeoplasmsMaleMiddle AgedModels, StatisticalRegistriesSex FactorsSmokingTime FactorsConceptsAge-adjusted incidence ratesMajor histologic typesOverall age-adjusted incidence rateAge-specific incidence ratesHistologic typeLung cancer incidenceLung cancerIncidence rateBirth cohortRecent birth cohortsIncidence patternsObserved time trendsCell carcinomaCancer incidenceTime trendsConnecticut Tumor RegistryIncidence of adenocarcinomaSmall cell carcinomaSquamous cell carcinomaLung cancer casesRecent epidemiologic studiesDifferent histologic typesDifferent incidence patternsObserved incidence patternsTumor RegistryTime trends in the incidence of renal carcinoma: Analysis of connecticut tumor registry data, 1935‐1989
Katz D, Zheng T, Holford T, Flannery J. Time trends in the incidence of renal carcinoma: Analysis of connecticut tumor registry data, 1935‐1989. International Journal Of Cancer 1994, 58: 57-63. PMID: 8014016, DOI: 10.1002/ijc.2910580111.Peer-Reviewed Original ResearchConceptsTransitional cell carcinomaConnecticut Tumor RegistryCell carcinomaIncidence rateRenal cancerPopulation-based cancer registriesIncidence of adenocarcinomaTime trendsCohort effectsRegression modellingEffect of ageTumor RegistryCancer RegistryIncident casesUrinary tractRenal carcinomaBirth cohortCarcinomaAdenocarcinomaRate of riseIncidenceNegative cohort effectRegistryCancerMales
1993
The time trend and age—period—cohort effects on incidence of adenocarcinoma of the stomach in connecticut from 1955–1989
Zheng T, Mayne S, Holford T, Boyle P, Liu W, Chen Y, Mador M, Flannery J. The time trend and age—period—cohort effects on incidence of adenocarcinoma of the stomach in connecticut from 1955–1989. Cancer 1993, 72: 330-340. PMID: 8319166, DOI: 10.1002/1097-0142(19930715)72:2<330::aid-cncr2820720205>3.0.co;2-l.Peer-Reviewed Original ResearchConceptsDistal stomachGastric cardiaObserved time trendsRisk factorsIncidence rateBirth cohortAge-adjusted incidence ratesTime trendsDifferent epidemiologic featuresFuture analytic studiesIncrease of adenocarcinomaConnecticut Tumor RegistryIncidence of adenocarcinomaRisk of adenocarcinomaBirth-cohort phenomenonRegression modelingUnited States populationUnspecified subsiteRetinol intakeHiatal herniaTumor RegistryEpidemiologic featuresAlcohol intakeIncident casesEtiologic factors
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply